Vertex Pharmaceuticals Inc's Comment on Supply Chain
The company sources raw materials and manufacturing services globally, utilizing multiple suppliers and third-party contract manufacturers, including some in China. These manufacturers provide raw materials, convert them into drug substances, and produce final dosage forms. The company maintains secondary sources for most commercial products and primarily conducts small molecule drug manufacturing in the United States. Manufacturing biologics and cell and genetic therapies involves specialized, customized processes and significant investment in manufacturing infrastructure, including cGMP clinical manufacturing. The company relies on third-party manufacturers for cell culture reagents and gene-editing components such as Cas9 protein and guide RNA molecules for CASGEVY, as well as for generating gene-edited cells. The CASGEVY manufacturing process includes multiple coordinated steps among the company, authorized treatment centers, third-party manufacturers, and shipping vendors. The company is investing to enhance CASGEVY manufacturing capacity and logistics and has established cell therapy manufacturing capabilities at its Boston facilities.
Vertex Pharmaceuticals Inc's Comment on Supply Chain
The company sources raw materials and manufacturing services globally, utilizing multiple suppliers and third-party contract manufacturers, including some in China. These manufacturers provide raw materials, convert them into drug substances, and produce final dosage forms. The company maintains secondary sources for most commercial products and primarily conducts small molecule drug manufacturing in the United States. Manufacturing biologics and cell and genetic therapies involves specialized, customized processes and significant investment in manufacturing infrastructure, including cGMP clinical manufacturing. The company relies on third-party manufacturers for cell culture reagents and gene-editing components such as Cas9 protein and guide RNA molecules for CASGEVY, as well as for generating gene-edited cells. The CASGEVY manufacturing process includes multiple coordinated steps among the company, authorized treatment centers, third-party manufacturers, and shipping vendors. The company is investing to enhance CASGEVY manufacturing capacity and logistics and has established cell therapy manufacturing capabilities at its Boston facilities.
Sources:
Vertex Pharmaceuticals Inc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Vertex Pharmaceuticals Inc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
